Randomized, double-blind, placebo-controlled, clinical study on the effect of Diabetinol(®) on glycemic control of subjects with impaired fasting glucose.

CONCLUSION: The current study suggests a role for Diabetinol(®) as an adjunctive therapy for glycemic maintenance and for decreasing the risk of diabetes-associated comorbidities in type 2 diabetic patients on conventional therapies. PMID: 26150732 [PubMed]

http://www.ncbi.nlm.nih.gov/pubmed/26150732?dopt=Abstract

Source: Diabetes Metab - July 11, 2015 Category: Endocrinology Authors: Evans M, Judy WV, Wilson D, Rumberger JA, Guthrie N Tags: Diabetes Metab Syndr Obes Source Type: research